Skip to main content
SpringerLink
Log in

Neuer Standard beim Mantelzelllymphom: „das Ende einer Epoche“

Interview mit Prof. Dr. Martin Dreyling, Leiter des Zentrums für maligne Hämatologie (HaemaKuM) am Klinikum der Universität München

  • Interview
  • Published:
best practice onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Dreyling M et al (2022) Efficacy and safety of Ibrutinib combined with standard first-line treatment or as substitute for autologous stem cell transplantation in younger patients with mantle cell lymphoma: results from the randomized triangle trial by the European MCL network. ASH. 2022, S Abstr 1 https://doi.org/10.1182/blood-2022-163018

    Book  Google Scholar 

  2. Wang LM et al (2022) Primary results from the phase 3 SHINE study of ibrutinib in combination with bendamustine-rituximab (BR) and R maintenance as a first-line treatment for older patients with mantle-cell lymphoma. EHA. 2022, S Abstr S209

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Neuer Standard beim Mantelzelllymphom: „das Ende einer Epoche“. best practice onkologie 18, 154–159 (2023). https://doi.org/10.1007/s11654-023-00480-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11654-023-00480-1

Search

Navigation